Scholarlink

Purpose <p>Chemotherapy induced ototoxicity (e.g. by cisplatin) is a regularly occurring although underreported challenge in clinical practice. Several reviews of ototoxicity monitoring throughout clinical trials reveal difficulty in estimating the incidence due to the use of different scales and classification systems. In this communication, we introduce a scale &#xa0;to improve the assessment of ototoxicity during routine cancer care incorporating patient reported outcomes.</p> Methods <p>Combining and updating the existing ototoxicity scales to develop a new and universally applicable grading scale.</p> Results <p>The developed scale includes all types of ototoxicity (hearing loss as well as tinnitus) and combines audiogram measurements with patient reported outcomes.</p> Conclusion <p>Using a single scale for assessing and grading ototoxicity in routine care as well as in clinical trials may improve the current understanding of the actual incidence and actual patient burden of this toxicity. &#xa0;In addition, it could&#xa0; enhance the opportunities for intervention and/or aural rehabilitation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Improving the usability of grading scales for drug-induced ototoxicity with a focus on real world data collection

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月9日

查看全文
  • Melissa Koot,
  • Mirjam Crul,
  • Dorieke van Balen,
  • Tim Schutte

摘要

Purpose

Chemotherapy induced ototoxicity (e.g. by cisplatin) is a regularly occurring although underreported challenge in clinical practice. Several reviews of ototoxicity monitoring throughout clinical trials reveal difficulty in estimating the incidence due to the use of different scales and classification systems. In this communication, we introduce a scale  to improve the assessment of ototoxicity during routine cancer care incorporating patient reported outcomes.

Methods

Combining and updating the existing ototoxicity scales to develop a new and universally applicable grading scale.

Results

The developed scale includes all types of ototoxicity (hearing loss as well as tinnitus) and combines audiogram measurements with patient reported outcomes.

Conclusion

Using a single scale for assessing and grading ototoxicity in routine care as well as in clinical trials may improve the current understanding of the actual incidence and actual patient burden of this toxicity.  In addition, it could  enhance the opportunities for intervention and/or aural rehabilitation.